BlackRock, Inc. 13D and 13G filings for Sorrento Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-03-08 2:19 pm Sale | 2023-02-28 | 13G | Sorrento Therapeutics, Inc. SRNE | BlackRock Inc. BLK | 75,749 0.000% | -39,347,892 (-99.81%) | Filing |
| 2023-02-03 4:27 pm Purchase | 2022-12-31 | 13G | Sorrento Therapeutics, Inc. SRNE | BlackRock Inc. BLK | 39,423,641 8.400% | 17,647,776 (+81.04%) | Filing |
| 2022-02-07 4:40 pm Purchase | 2021-12-31 | 13G | Sorrento Therapeutics, Inc. SRNE | BlackRock Inc. BLK | 21,775,865 6.900% | 4,156,187 (+23.59%) | Filing |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Sorrento Therapeutics, Inc. SRNE | BlackRock Inc. BLK | 17,619,678 6.700% | 8,829,581 (+100.45%) | Filing |
| 2020-04-09 5:15 pm Purchase | 2020-03-31 | 13G | Sorrento Therapeutics, Inc. SRNE | BlackRock Inc. BLK | 8,790,097 4.800% | 147,039 (+1.70%) | Filing |